Understanding Your Wegovy Starter Dose Options
Switching to Wegovy from Mounjaro: Understanding the 0.25mg Starting Point
When switching to Wegovy from Mounjaro, patients begin with the standard 0.25mg starter dose regardless of their previous tirzepatide dosing. This approach ensures safe introduction to semaglutide's GLP-1 receptor mechanism, which differs from Mounjaro's dual GIP and GLP-1 action. The 0.25mg dose serves as a four-week acclimatisation period, allowing your body to adjust to Wegovy's appetite-regulating effects whilst minimising potential gastrointestinal side effects. This prescription-only medicine requires careful dose escalation that cannot be rushed or skipped, even for patients previously stable on higher Mounjaro doses.
The transition period between stopping Mounjaro and starting Wegovy should be discussed with your prescriber, as both medications have different half-lives and clearance rates. Most clinical guidance suggests a washout period, though individual circumstances may vary based on your response to previous treatment. Starting fresh with Wegovy's 0.25mg dose allows for proper clinical monitoring and ensures you receive the full benefit of the structured escalation schedule that has been proven effective in clinical trials.
Wegovy Starter Dose Pricing and Bundle Options for Mounjaro Switchers
EverydayMeds offers Wegovy 0.25mg starter pens from £79.99, with new customers applying code FIRST40 at checkout to reach this price point. For patients switching to Wegovy from Mounjaro who want to secure their progression doses, the Intro Duo bundle provides both 0.25mg and 0.5mg pens for £169.99, covering your first two months of treatment. This eliminates the need for multiple orders and ensures Reliable Supply continuity during your critical transition period. Returning customers can use code DOSE25 for ongoing orders after their initial purchase.
The Intro Trio bundle extends this convenience further, including 0.25mg, 0.5mg, and 1mg doses for £299.99, providing three months of progressive treatment in a single order. This option particularly suits patients switching to Wegovy from Mounjaro who prefer fewer ordering touchpoints whilst establishing their new routine. All bundles include next-day cold-chain delivery from our GPhC-registered facility #9012878, ensuring your medication arrives in optimal condition regardless of seasonal temperature variations.
Clinical Evidence Supporting Switching to Wegovy from Mounjaro
The STEP clinical trial programme demonstrates semaglutide's efficacy when initiated with proper dose escalation from the 0.25mg starting point. In STEP 1, patients achieved approximately 15% average weight loss at 68 weeks when taking Wegovy alongside a reduced-calorie diet and increased physical activity, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). These results were achieved following the exact escalation schedule that begins with the 0.25mg starter dose you'll receive when switching to Wegovy from Mounjaro.
While direct head-to-head trials between semaglutide and tirzepatide are limited, both mechanisms offer distinct approaches to weight management through appetite regulation. The STEP trials' consistent methodology provides robust evidence for Wegovy's approach, though individual responses may vary when switching to Wegovy from Mounjaro based on personal factors including previous treatment response, metabolic profile, and adherence to lifestyle modifications.
How Wegovy Works Differently from Mounjaro
Wegovy contains semaglutide, a selective GLP-1 receptor agonist that mimics your body's natural incretin hormone to promote satiety and reduce appetite through direct action on brain appetite centres. Unlike Mounjaro's dual GIP and GLP-1 receptor activation, Wegovy focuses specifically on the GLP-1 pathway, which may result in different appetite suppression patterns and side effect profiles. The medication works by slowing gastric emptying, enhancing glucose-dependent insulin secretion, and directly influencing hypothalamic appetite control centres. This targeted approach may suit patients who experienced specific responses to the GLP-1 component of their previous Mounjaro treatment. Understanding this mechanistic difference helps explain why the 0.25mg starter dose remains necessary even when switching from established Mounjaro therapy.
Your Wegovy Ordering Process When Switching from Mounjaro
Starting Wegovy requires completion of EverydayMeds' 3-minute online clinical assessment, which evaluates your suitability for semaglutide therapy and considers your previous Mounjaro experience. This assessment captures relevant information about your weight management journey, current medications, and any side effects experienced with previous GLP-1-based treatments. Following submission, our clinical team reviews your assessment within 3 working days (or 24 hours with express service), ensuring appropriate prescribing for your transition to Wegovy. Once approved, your 0.25mg starter dose ships via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements essential for medication stability. The entire process from assessment to delivery typically completes within 4-5 working days, allowing for seamless transition planning.
Storage Advantages When Switching to Wegovy from Mounjaro
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable for up to 6 weeks at room temperature below 30°C once removed from refrigeration. This advantage proves particularly valuable for patients with active lifestyles, frequent travel, or limited refrigeration access, providing triple the room temperature stability of Mounjaro's 21-day limit. The FlexTouch pen design delivers consistent, accurate dosing with an easy-to-read dose counter and simple injection mechanism. Your dose escalation follows a structured 16-week schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, then 2.4mg maintenance from week 17 onwards. This graduated approach, starting with your £79.99 starter dose, ensures optimal tolerability whilst building towards therapeutic effectiveness.
Transition Timeline Considerations When Switching to Wegovy from Mounjaro
The decision to switch to Wegovy from Mounjaro often stems from storage convenience requirements, side effect profiles, or formulary considerations rather than efficacy concerns. Patients frequently appreciate Wegovy's extended room temperature stability for travel or work situations where refrigeration proves challenging. The transition requires restarting with the 0.25mg dose regardless of your final Mounjaro dose, as the different receptor mechanisms necessitate fresh tolerance establishment.
Your prescriber will determine appropriate timing for stopping Mounjaro and initiating Wegovy based on individual factors including treatment response, side effect history, and clinical goals. Some patients find the single GLP-1 mechanism provides more predictable effects compared to Mounjaro's dual pathway approach. The key advantage of switching to Wegovy from Mounjaro often relates to practical convenience factors rather than dramatic efficacy differences.
Complete Your Wegovy Transition with EverydayMeds
Ready to begin switching to Wegovy from Mounjaro with the essential 0.25mg starter dose? Visit https://everydaymeds.co.uk/products/wegovy-0-25mg to complete your clinical assessment and secure your first month's supply from £79.99. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 for ongoing orders. Our GPhC-registered clinical team #9012878 ensures safe, appropriate prescribing for your weight management transition. Both Wegovy and Mounjaro remain available from EverydayMeds, providing flexibility for your ongoing treatment decisions. Trust our established cold-chain delivery process and comprehensive clinical support to make your switch to Wegovy as smooth and successful as possible.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
